Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Royal jelly contains unique bioactive compounds including 10-hydroxy-2-decenoic acid (10-HDA) and major royal jelly protein 1 (MRJP1) that modulate estrogen receptors, inhibit histone deacetylases, and regulate inflammatory pathways. These mechanisms support its documented effects on immune function, hormonal balance, and neuroprotection through AMPK/PI3K/AKT signaling pathways.
Reported Benefits (Provisional)
Origin & History
Royal Jelly is a nutrient-rich secretion produced by worker bees (Apis mellifera) to nourish the queen bee and young larvae. It is globally sourced from regions where these bees thrive, including Europe, Asia, and the Americas. This unique substance is prized in functional nutrition for its complex bioactive profile, supporting cellular regeneration and overall vitality.
Research Narrative (Provisional)
Research indicates Royal Jelly's potential in neuroprotection, immune modulation, and hormonal regulation, with studies exploring its effects on cognitive function and menopausal symptoms. Evidence also supports its role in skin health and cardiovascular parameters. Further human clinical trials are ongoing to fully elucidate its broad spectrum of benefits.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- All nine essential amino acids - B vitamins (B5, B6) - Calcium, Potassium, Magnesium, Zinc, Iron - Royalactin (cellular regeneration and longevity) - 10-HDA (immune-boosting and anti-inflammatory fatty acid) - Acetylcholine (neurotransmitter precursor) - Flavonoids, Polyphenols (antioxidants)
Reported Mechanism (Provisional)
10-Hydroxy-2-decenoic acid (10-HDA) binds to estrogen receptors (ERα/ERβ) with -6.3 kcal/mol affinity and inhibits histone deacetylases to alter gene expression. Major royal jelly protein 1 (MRJP1) promotes cell proliferation and albumin synthesis while royal jelly acid modulates p-JNK, p-p38, and NF-κB pathways. These compounds collectively enhance FOXO1-mediated autophagy and activate AMPK/PI3K/AKT signaling for neuroprotection and immune modulation.
Clinical Narrative (Provisional)
Current evidence relies primarily on preclinical in vitro and animal studies, with limited large-scale human clinical trials available. Research demonstrates 10-HDA's HDAC binding affinity and royal jelly acid's dose-dependent inhibition of cancer cells through complement and coagulation pathways. While rat hepatocyte studies show MRJP1's cell proliferation effects and S. aureus biofilm inhibition has been documented, specific numerical outcomes from human trials are lacking. Further clinical validation through randomized controlled trials is needed to confirm therapeutic efficacy and establish dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.